Exelixis, Inc. (EXEL) is a leading biopharmaceutical company that is ideally positioned to focus on the discovery, development, and commercialization of new and innovative medicines that can drastically enhance the lives of patients battling cancer. The company is headquartered in Alameda, California, and has been in operation since 1994.
Exelixis is best known for its targeted therapy drug, Cabometyx (cabozantinib), which is approved for the treatment of several types of cancers, including advanced renal cell carcinoma (RCC, a type of kidney cancer) and hepatocellular carcinoma (HCC, a type of liver cancer). The drug works by blocking the growth of new blood vessels that feed a tumor. Apart from Cabometyx, Exelixis has also developed other drugs such as Cometriq and Cotellic, and is continuously working on new drug candidates to further expand its product portfolio.
The company operates on a business model that combines internal product development with strategic corporate alliances and business development activities. This strategy has allowed Exelixis to access resources, share risk and attract significant capital over the course of its existence, thereby building a robust product pipeline and achieving financial stability.
Exelixis, Inc. is deeply committed to the principle of doing "good science that matters." The company employs a team of skilled, passionate professionals who are relentless in their pursuit of new scientific understandings and clinical breakthroughs. Exelixis highly values collaboration, teamwork, and integrity, ensuring a conducive working environment for innovation to flourish.
Corporate social responsibility is also a key component of Exelixis' mission. The company is committed to improving access to its therapies, supporting patient groups and contributing to the broader community. It is also focused on reducing its environmental impact and promoting sustainable practices.
On the financial front, Exelixis continues to deliver strong performance with a steady stream of revenue from its approved products and clinical developments. It has a solid balance sheet with sufficient liquidity to meet its expansion requirements and uphold research and development activities.
In the ever-evolving biopharmaceutical industry, Exelixis offers a compelling mix of current successful cancer treatments and promising pipeline products, a sound business strategy, robust financial health and a strong commitment to patients. This positions them firmly for continued growth and further achievements in their mission to help cancer patients recover stronger and live longer.